William Blair Has Positive Forecast for ADPT FY2025 Earnings

Key Points

• William Blair has raised its fiscal year 2025 earnings per share estimate for Adaptive Biotechnologies from ($0.91) to ($0.81), indicating improved expectations for the company.
• Adaptive Biotechnologies reported $49.94 million in revenue for the recent quarter, exceeding analyst expectations, and showed a year-over-year revenue increase of 36.3%.
• Shares of ADPT are currently down 4.9%, trading at $11.92, while the stock has a consensus rating of "Moderate Buy" with a price target of $12.38.

Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Free Report) - Analysts at William Blair lifted their FY2025 earnings estimates for shares of Adaptive Biotechnologies in a research report issued to clients and investors on Wednesday, August 6th. William Blair analyst A. Brackmann now anticipates that the company will post earnings of ($0.81) per share for the year, up from their previous estimate of ($0.91). The consensus estimate for Adaptive Biotechnologies' current full-year earnings is ($0.92) per share. William Blair also issued estimates for Adaptive Biotechnologies' Q1 2026 earnings at ($0.18) EPS, Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.13) EPS and FY2026 earnings at ($0.64) EPS.

ADPT has been the topic of a number of other reports. Morgan Stanley boosted their price target on shares of Adaptive Biotechnologies from $7.00 to $9.00 and gave the stock an "equal weight" rating in a research note on Monday, May 5th. JPMorgan Chase & Co. boosted their price target on shares of Adaptive Biotechnologies from $10.00 to $14.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 6th. Craig Hallum started coverage on shares of Adaptive Biotechnologies in a research note on Wednesday, June 18th. They set a "buy" rating and a $15.00 target price on the stock. Piper Sandler upped their target price on shares of Adaptive Biotechnologies from $13.00 to $15.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 6th. Finally, TD Cowen upped their target price on shares of Adaptive Biotechnologies from $13.00 to $15.00 and gave the stock a "buy" rating in a research note on Wednesday, August 6th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $12.38.

Adaptive Biotechnologies Stock Up 3.9%

NASDAQ:ADPT traded up $0.48 on Friday, reaching $12.63. 1,218,909 shares of the company's stock were exchanged, compared to its average volume of 2,042,500. The firm has a market capitalization of $1.92 billion, a price-to-earnings ratio of -15.45 and a beta of 1.92. The business has a fifty day moving average of $10.97 and a 200-day moving average of $9.13. Adaptive Biotechnologies has a 52-week low of $3.98 and a 52-week high of $12.93.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.07. The firm had revenue of $49.94 million for the quarter, compared to analyst estimates of $49.40 million. Adaptive Biotechnologies had a negative net margin of 59.07% and a negative return on equity of 60.93%. Adaptive Biotechnologies's revenue was up 36.3% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.31) EPS.

Hedge Funds Weigh In On Adaptive Biotechnologies

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC boosted its holdings in Adaptive Biotechnologies by 35.6% in the fourth quarter. Renaissance Technologies LLC now owns 229,785 shares of the company's stock valued at $1,378,000 after purchasing an additional 60,385 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Adaptive Biotechnologies by 36.5% in the first quarter. GAMMA Investing LLC now owns 13,393 shares of the company's stock valued at $100,000 after acquiring an additional 3,583 shares during the period. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Adaptive Biotechnologies in the first quarter valued at approximately $87,000. Janus Henderson Group PLC acquired a new stake in shares of Adaptive Biotechnologies in the fourth quarter valued at approximately $281,000. Finally, Exchange Traded Concepts LLC acquired a new stake in shares of Adaptive Biotechnologies in the first quarter valued at approximately $634,000. 99.17% of the stock is owned by institutional investors and hedge funds.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.